Get the Stockscreener App
116.38
2.46%
-2.94
After Hours:
116.38
Illumina Inc stock is traded at $116.38, with a volume of 2.03M.
It is down -2.46% in the last 24 hours and down -17.50% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$119.32
Open:
$118.29
24h Volume:
2.03M
Relative Volume:
1.10
Market Cap:
$17.78B
Revenue:
$4.29B
Net Income/Loss:
$703.00M
P/E Ratio:
26.07
EPS:
4.4635
Net Cash Flow:
$993.00M
1W Performance:
-13.27%
1M Performance:
-17.50%
6M Performance:
+22.79%
1Y Performance:
+15.59%
1-Day Range:
$116.20
$119.17
1-Week Range:
$115.20
$136.15
52-Week Range:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
116.38 | 18.23B | 4.29B | 703.00M | 993.00M | 4.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
527.17 | 202.81B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
219.98 | 155.34B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
648.73 | 51.63B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
128.90 | 36.49B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
329.20 | 32.08B | 3.11B | 648.81M | 602.27M | 10.88 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Scott Gottlieb Buys 200 Shares of Illumina (NASDAQ:ILMN) Stock - MarketBeat
Ngs Oncology Market Is Going to Boom | Illumina • Roche • Thermo Fisher Scientific - openPR.com
Simplifying library prep: All in a day’s work for Louise Fraser - Illumina
Illumina Looks To Clinical Consumables And China Restart To Offset Intensifying NGS Price Pressure - Citeline News & Insights
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewswire Inc.
Spatial Genomics and Transcriptomics Market size to cross - openPR.com
Illumina, Inc. $ILMN Shares Sold by GUARDCAP ASSET MANAGEMENT Ltd - MarketBeat
Multiomics Market Forecast Through 2033: Size, Share, Trends, - openPR.com
My path to Illumina - Illumina
Unlocking Illumina (ILMN) International Revenues: Trends, Surprises, and Prospects - Nasdaq
This Week in Chancery Court: Trump Media SPAC Appeal, Illumina - Bloomberg Law News
Illumina Crash 10% on Earnings: Why the Stock Could Rebound to $185 in 2026 - TIKR.com
Illumina, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - 富途牛牛
Is Illumina’s (ILMN) Clinical Consumables Surge Quietly Redefining Its Core Investment Story? - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL) - The Globe and Mail
Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus - TechStock²
Illumina, Inc.'s (NASDAQ:ILMN) Business Is Yet to Catch Up With Its Share Price - 富途牛牛
Illumina Enters Oversold Territory (ILMN) - Nasdaq
UBS Adjusts Illumina Price Target to $135 From $120, Maintains Neutral Rating - marketscreener.com
Molina Healthcare, Coty, Illumina, Amazon and other big stocks moving lower in Friday's pre-market session - MSN
Principal Financial Group Inc. Sells 17,431 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Q4 2025 Earnings Call Transcript - Insider Monkey
Illumina revenue up 5% to USD 1.16B in Q4 2025 - Medical Buyer
ILMN Q4 Deep Dive: Clinical Consumables Growth, Multiomics Expansion, and Margin Momentum - Yahoo Finance
Illumina Q4 2025 slides: Clinical growth accelerates as NovaSeq X transition advances By Investing.com - Investing.com South Africa
Illumina Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Illumina beats Q4 2025 EPS forecast by 10.66% - Investing.com Canada
Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Illumina Q4 2025 slides: Clinical growth accelerates as NovaSeq X transition advances - Investing.com
Illumina Inc (NASDAQ:ILMN) Stock Falls Despite Q4 Earnings Beat on Cautious 2026 Outlook - Chartmill
Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates - Nasdaq
Illumina (NASDAQ:ILMN) Posts Quarterly Earnings Results - MarketBeat
Illumina: Q4 Earnings Snapshot - kens5.com
Illumina shares tumble as flat revenue disappoints investors By Investing.com - Investing.com South Africa
Illumina (NASDAQ:ILMN) Issues FY 2026 Earnings Guidance - MarketBeat
Illumina Inc. Q4 Profit Advances - Nasdaq
Illumina Q4 Non-GAAP Earnings, Revenue Rise; 2026 Outlook Set - marketscreener.com
Illumina (NASDAQ:ILMN) Reports Bullish Q4 CY2025 - TradingView
Illumina Q4 Earnings Summary & Key Takeaways - Benzinga
Earnings Flash (ILMN) Illumina, Inc. Reports Q4 Revenue $1.16B, vs. FactSet Est of $1.12B - marketscreener.com
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 - PR Newswire
Illumina earnings loom as investors seek clarity on 2026 outlook By Investing.com - au.investing.com
Illumina Wildlife Genomics Deal Highlights New Conservation And Valuation Story - Sahm
Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics - Yahoo Finance
Multi-Omics Market Set for Explosive Growth to USD 33.25 Billion - openPR.com
San Diego Zoo’s Frozen Zoo Gets Genomic Boost - Newsradio 600 KOGO
Synthetic Biology Market Set for Explosive Growth to USD 67.47 - openPR.com
Mediolanum International Funds Ltd Makes New $914,000 Investment in Illumina, Inc. $ILMN - MarketBeat
Illumina (ILMN) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
National Pension Service Buys 10,529 Shares of Illumina, Inc. $ILMN - MarketBeat
What Catalysts Are Shifting The Illumina (ILMN) Story For 2026 And Beyond - Yahoo Finance
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.93%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):